Drugs / Reparixin
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02001974 | Feb 2012 → Jun 2014 | breast cancer | Dompé Farmaceutici S.p.A | Completed | No outcome recorded |
| Phase 29 trials · 5 missed | ||||||
| Phase 2 | NCT05835466 | Jul 2023 → Dec 2027 expected | myelofibrosis, primary myelofibrosis | Icahn School of Medicine at Mount Sinai | Recruiting | No outcome recorded |
| Phase 2 | NCT05496868 | Dec 2022 → Mar 2025 | adult acute respiratory distress syndrome | Dompé Farmaceutici S.p.A | Completed | Missed primary |
| Phase 2 | NCT05212701 | Apr 2022 → Jun 2023 | breast cancer | Dompé Farmaceutici S.p.A | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02370238 | Jul 2015 → Feb 2019 | breast cancer | Dompé Farmaceutici S.p.A | Completed | Missed primary |
| Phase 2 | NCT03031470 | Mar 2015 → Feb 2017 | disease related to transplantation, hepatic infarction | Dompé Farmaceutici S.p.A | Terminated | Missed primary |
| Phase 2 | NCT01861054 | Feb 2013 → Mar 2015 | breast cancer | Dompé Farmaceutici S.p.A | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01220856 | Jul 2010 → Apr 2013 | type 1 diabetes mellitus | Dompé Farmaceutici S.p.A | Completed | No outcome recorded |
| Phase 2 | NCT00248040 | Oct 2005 → May 2008 | ischemic disease, kidney disorder | Dompé Farmaceutici S.p.A | Completed | Missed primary |
| Phase 2 | NCT00224406 | May 2005 → Sep 2006 | ischemic disease | Dompé Farmaceutici S.p.A | Completed | Missed primary |
| Phase 2/32 trials · 1 met primary · 1 missed | ||||||
| Phase 2/3 | NCT04794803 | May → Nov 2020 | pneumonia | Dompé Farmaceutici S.p.A | Terminated | Met primary |
| Phase 2/3 | NCT01967888 | Feb 2014 → Jan 2018 | chronic pancreatitis | Dompé Farmaceutici S.p.A | Completed | Missed primary |
| Phase 33 trials · 2 missed | ||||||
| Phase 3 | NCT05254990 | Apr 2022 → Jul 2024 | COVID-19, pneumonia | Dompé Farmaceutici S.p.A | Terminated | No outcome recorded |
| Phase 3 | NCT04878055 | Feb → Sep 2021 | viral pneumonia | Dompé Farmaceutici S.p.A | Completed | Missed primary |
| Phase 3 | NCT01817959 | Oct 2012 → Dec 2016 | type 1 diabetes mellitus | Dompé Farmaceutici S.p.A | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-06-13 | Dompé Farmaceutici S.p.A | Results Dompé Announces Results of Phase 2 Study Evaluating the Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia dompe.com ↗
In hospitalized patients with COVID-19 Pneumonia, the rates of clinical events among those treated with Reparixin (n=36) were statistically significantly lower than standard of care (n=19). |
| 2020-09-01 | Dompé Farmaceutici S.p.A | Regulatory COVID-19 - Brazilian Health Regulatory Agency (ANVISA) authorizes Dompé’s REPAVID-19, a Phase 2 Clinical Trial for Treatment of Severe Patients dompe.com ↗
Sept. 1, 2020 - Brazil’s Health Regulatory Agency, ANVISA, has greenlighted Dompé’s REPAVID-19, Clinical Trial of Reparixin for Treatment of Severe Covid-19 Patients. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-06-13 | Dompé Farmaceutici S.p.A | Dompé Announces Results of Phase 2 Study Evaluating the Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia dompe.com ↗ |
| 2021-06-03 | Dompé Farmaceutici S.p.A | Dompé Announces Activation of U.S. Clinical Trial Sites for Phase 3 Study of Reparixin, an Oral Investigational CXCR1/CXCR2 Inhibitor, in Hospitalized Patients with Severe COVID-19 Pneumonia dompe.com ↗ |
| 2020-09-01 | Dompé Farmaceutici S.p.A | COVID-19 - Brazilian Health Regulatory Agency (ANVISA) authorizes Dompé’s REPAVID-19, a Phase 2 Clinical Trial for Treatment of Severe Patients dompe.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Reparixin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02370238 ↗ |
| Known as | DF 1681Y | ChEMBL registry synonym — accepted as the source's own label CHEMBL191413 ↗ |
| Known as | Reparixina | ChEMBL registry synonym — accepted as the source's own label CHEMBL191413 ↗ |
| Known as | Reparixine | ChEMBL registry synonym — accepted as the source's own label CHEMBL191413 ↗ |
| Known as | Repertaxin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00224406 ↗ |
| Action | Inhibit | “CXCL8 (CXC ligand 8 \\[formerly interleukin (IL)-8\\]) inhibition with repertaxin” NCT00224406 ↗ |
| Modality | Small molecule | “Reparixin is the first low molecular weight blocker of CXCL8 biological activity in clinical development.” NCT01817959 ↗ |
| Route | Intravenous | “The Investigational Product was administered as an intravenous infusion into a (high flow) central vein or through an arterio-venous fistula, by an infusion pump adequate to...” NCT00248040 ↗ |
| Target | CXCL8 | “Reparixin is a novel, specific inhibitor of CXCL8.” NCT00248040 ↗ |
| Target | CXCR2 | “Interleukin-8 receptor B modulator” CHEMBL191413 ↗ |